SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
SeaStar Medical announced strong second quarter 2026 financial results, highlighted by an 82% increase in net revenue from its QUELIMMUNE pediatric acute kidney injury (AKI) therapy compared to Q2 2025. The company expanded its pediatric customer base, progressed enrollment in its pivotal NEUTRALIZE-AKI clinical trial targeting adult AKI patients, …